Back

AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 5 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Marcin Ufnal

Medical University of Warsaw, Warsaw (Poland)

5 More presentations in this session

Presentation thumbnail
The impact of modifiable risk factors on readmissions during the vulnerable period in patients with heart failure
Assistant Professor A. Lacraru (Bucharest, RO)
Abstract Slides Video
Presentation thumbnail
Effect of intravenous FCM therapy on myocardial work indices in patients with HFrEF and ID.
Professor A. Safarova (Baku, AZ)
Abstract Slides Video
Presentation thumbnail
Prospective evaluation of sacubitril/valsartan utilization patterns and clinical outcomes in Korean patients with heart failure with reduced ejection fraction: real-world post-marketing surveillance
Professor J. Choi (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
ARNi treatment in adults with Tetralogy of Fallot: a single-centre experience
Doctor A. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Effect of guideline-recommended medical therapy according to blood urea nitrogen
Doctor P. Tolomeo (Glasgow, GB)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 5

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
AZD3427, a novel relaxin receptor agonist and impact on renal perfusion in patients with heart failure with reduced ejection rraction: the phase 1b Re-Perfuse study design
thumbnail
Congress Presentation
Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.
thumbnail
Congress Presentation
Long-acting CRF2 receptor agonist COR-1389 improves cardiopulmonary function parameters in monocrotaline-induced pulmonary hypertension and right heart failure rat model

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources